The results in Figure 5A indicate that TP53 had a significantly (p < 0.05) positive correlation with BAX expression in LUAD, UCEC, COAD, STAD, and GBM patients, being also positively and significantly correlated (p < 0.05) with BCL2L1 expression levels in STAD patients. This evidence concerns the gene TP53 and gastric adenocarcinoma.